Glovax Lifescience Corporation is a fully integrated vaccine company seeking to drastically improve immunization coverage in the country, primarily for middle to low income Filipinos, by finding innovative ways to increase the availability, affordability, and awareness of vaccines.
We are open to partnering up with individuals or organizations who share our vision of a healthier Philippines. If you're interested, please send us a message through the form on the right (swipe to reveal):
This is a temporary landing page. Just like our cutting edge vaccine and biotech research and development facility, our website is also currently under construction. Please stay tuned for a more comprehensive site to launch soon. Thank you for visiting.
At present, we are devoting much of our attention and resources to help alleviate the spread of Covid-19 in the Philippines.
We have recently partnered with Korean firm EuBiologics to locally produce and distribute EuCorVac-19 which was developed in the United States by POP Biotechnologies. EuCorVac-19 is a genetic recombinant with a vaccine adjuvant and has demonstrated excellent immunogenicity and safety. Unlike other Covid-19 vaccines, it does not require cryogenic temperature, making storage and distribution more convenient as well as helping keep costs down.
We are in the early stages of constructing a state of the art vaccine and biotech research and development facility, that will allow us to produce 100 million doses of EuCorVac-19 every year, as well as vaccines for other diseases. We are targeting the facility to be operational by the end of 2022. In the meantime, we are intend to import EuCorVac-19 from Korea to help increase the Philippines’ supply of Covid-19 vaccine.
Glovax Lifescience Corporation finds its roots back in 2003, from a seed capital of ₱80,000 which was mostly raised by our founder, Giovanni Alingog, by selling off their wedding gifts.
In 2009, we became the first and only company to bring in a AH1N1 Swine flu vaccine which helped the Philippines keep the pandemic in check.
Come 2015, with the business in full swing, Glovax Lifescience Corporation is now at the forefront of the Philippines’ efforts to become self-reliant against deadly diseases, especially during times of pandemic such as the aforementioned AH1N1, SARS, and even Ebola, by discovering, developing, and distributing new vaccines.
With the assistance of Rotary International, Philippine Institute of Certified Public Accountants (PICPA) local government units, and non-government organizations, we have vaccinated a total of 133,000 underprivileged individuals for free. The vaccines we provided such as the ones for meningococcemia, pneumonia, and influenza are not given away by the government.
Our vaccination program has benefitted residents as far off as Patikul, Sulu; poverty-stricken areas in Quezon Province and Daet, Camarines Norte and impoverished communities in Metro Manila such as in Quezon City, Manila, Mandaluyong, and Pasay City.
